


SDZ 220-581

Chemical Properties

CAS No. : 174575-17-8
 Formula: C₁₆H₁₇ClNO₅P
 Molecular Weight: 369.74
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	SDZ 220-581 is a potent, orally bioavailable competitive NMDA receptor antagonist with a pKi value of 7.7.
Targets(IC50)	iGluR
In vivo	SDZ 220-581 (administered orally to male OF-1 mice at 3.2-32 mg/kg for 24 hours) exerts a dose-dependent protective effect against maximal electroshock seizure (MES) injury. Studies have shown that the protective effect of SDZ 220-581 is characterized by rapid onset and long duration of action [1].

Solubility Information

Solubility	DMSO: 6.8 mg/mL (18.39 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 0.5 mg/mL (1.35 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7046 mL	13.523 mL	27.046 mL
5 mM	0.5409 mL	2.7046 mL	5.4092 mL
10 mM	0.2705 mL	1.3523 mL	2.7046 mL
50 mM	0.0541 mL	0.2705 mL	0.5409 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Urwyler S, Campbell E, Fricker G, Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. *Neuropharmacology*. 1996 Jun;35(6):655-69.

Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. *Neuropharmacology*. 2013 Jan;64:224-39.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481